Drug metabolism and atypical antipsychotics (Q33697379)

28 July 2017

1 reference

title

Drug metabolism and atypical antipsychotics (English)

1 reference

28 July 2017

T I Prior

1

1 reference

28 July 2017

P S Chue

series ordinal

2

1 reference

28 July 2017

P Tibbo

series ordinal

3

1 reference

28 July 2017

G B Baker

series ordinal

4

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 June 1999

1 reference

European Neuropsychopharmacology

28 July 2017

published in

1 reference

28 July 2017

volume

9

1 reference

28 July 2017

issue

4

1 reference

28 July 2017

page(s)

301-309

1 reference

Cytochrome P4502D6 genotype does not determine response to clozapine

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects.

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

The pharmacogenetics of the selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Pharmacokinetics of clozapine and risperidone: a review of recent literature

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Erythromycin-induced clozapine toxic reaction

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Risperidone and Cytochrome P450 3A

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Elevated clozapine levels after fluvoxamine initiation

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Elevated clozapine plasma concentrations after fluvoxamine initiation

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Seizure following addition of erythromycin to clozapine treatment

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Cytochromes P450 expression systems

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Cigarette smoking and theophyiiine clearance and metabolism

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Interactions of Serotonin Reuptake Inhibitors With Tricyclic Antidepressants

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide*

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Pharmacokinetic Interaction of Clozapine and Rifampicin in a Forensic Patient With an Atypical Mycobacterial Infection

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Fluvoxamine increases the clozapine serum levels significantly

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Cross-tapering clozapine and risperidone

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Extrahepatic metabolism of drugs in humans

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors.

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Fluoroquinolone inhibition of clozapine metabolism

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Seizures following smoking cessation in a clozapine responder

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Pharmacokinetic Drug Interactions of New Antidepressants: A Review of the Effects on the Metabolism of Other Drugs

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Use of in vitro human metabolism studies in drug development. An industrial perspective

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

The metabolism of psychoactive drugs: a review of enzymatic biotransformation and inhibition

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Effect of clozapine on plasma nortriptyline concentration

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Pharmacokinetic interactions involving clozapine

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Pharmacokinetic interaction between risperidone and clozapine

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Interaction between caffeine and clozapine

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Genetically engineered bacterial cells and applications.

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

The influence of rifampin treatment on caffeine clearance in healthy man

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

The human hepatic cytochromes P450 involved in drug metabolism

1 reference

https://api.crossref.org/works/10.1016/S0924-977X(98)50040-6

7 January 2021

10.1016/S0924-977X(98)00040-6

Identifiers

DOI

1 reference

28 July 2017

1 reference